Subcutaneous Epcoritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 StudyJune 30th 2022
Dr. Tycel Phillips reviews pivotal dose-expansion results from the EPCORE NHL-1 trial on epcoritamab in patients with relapsed or refractory large B-cell lymphoma (LBCL).
Rapid Readout: Phase 1/2 Trial of Subcutaneous Epcoritamab With R-Squared in Patients with Relapsed or Refractory Follicular LymphomaFebruary 8th 2022
Tycel Phillips, MD, discusses a phase 1/2 trial combining subcutaneous epcoritamab with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.
Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCLJanuary 11th 2019
Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).
Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCLDecember 2nd 2018
Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.